In particular, IL-1β released by the activation of the NLRP3 inflammasome reduces tyrosine phosphorylation, and the negatively regulation of insulin receptor substrate 1 mRNA expression directly inhibits the insulin signaling pathway, leading to insulin resistance and type 2 diabetes mellitus (T2DM) [91, 92]. Here, NLRP3 is linked to type 2 diabetes mellitus.